ALLIANCE PHARMA PLC

Report Publication Announcement • Aug 17, 2015

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 1386W

Alliance Pharma PLC

17 August 2015

For immediate release	17 August 2015

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Notification of Interim Results

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, will announce its interim results for the six months ended 30 June 2015 on Wednesday 9 September 2015.

A briefing for analysts will be held at 11.00am on the morning of the results at the offices of Buchanan, 107 Cheapside, London EC2V 6DN.

For more information, or to register attendance, please contact Buchanan on 020 7466 5000.

For further information:

Alliance Pharma plc	+ 44 (0) 1249 466966
John Dawson, Chief Executive
Buchanan	+ 44 (0) 20 7466 5000
Mark Court / Sophie Cowles / Jane Glover
Numis Securities Limited	+ 44 (0) 20 7260 1000
Nominated Adviser: Michael Meade / Freddie Barnfield
Corporate Broking: David Poutney

Notes to editors:

About Alliance

Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has a strong track record of acquiring the rights to established niche products and owns or licenses the rights to more than 60 pharmaceutical products and continues to explore opportunities to expand the range.

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NORPIMJTMBJBBMA